BOB体育

Skip to main content
  • Determine effectiveness of Anifrolumab In SYstemic sclerosis (DAISY)

    The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013鈥�

    Investigator
    Michael R Bubb
    Ages
    18 Years - 70 Years
    Sexes
    All
  • M23 Select SLE

    Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active鈥�

    Investigator
    Michael R Bubb
    Ages
    18 Years - 63 Years
    Sexes
    All
  • BIIB059

    In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care鈥�

    Investigator
    Michael R Bubb
    Ages
    18 Years - N/A
    Sexes
    All
  • OCEANIC

    Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel). Atrial fibrillation is a condition of having鈥�

    Investigator
    Gabriel Bonnell
    Ages
    18 Years - N/A
    Sexes
    All
  • PROMISE III

    A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

    Investigator
    Benjamin N Jacobs
    Ages
    18 Years - 95 Years
    Sexes
    All
  • EXPAND II

    Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.

    Investigator
    Thomas M Beaver
    Ages
    65 Years - N/A
    Sexes
    All
  • TS MOD CM GPI

    The investigators will implant and monitor 8 research subjects with a subcortical closed-loop system for detection and suppression of tics. The project will use the FDA-approved "Medtronic Percept PC" device, which is an implantable neurostimulator鈥�

    Investigator
    Michael S Okun
    Ages
    18 Years - 85 Years
    Sexes
    All
  • Vercise DBS Registry

    The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming鈥�

    Investigator
    Michael S Okun
    Ages
    18 Years - N/A
    Sexes
    All